Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pentagum
- Development stage
- Preclinical
- Lead developer
- Lactea Therapeutics
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Oral
01
Overview
Pentagum is a pentagon-shaped chewing gum product developed by Lactea Therapeutics to support oral health and manage dental biofilms, particularly in austere environments where routine hygiene is limited, such as for military personnel. The product utilizes the company's proprietary Multifunctional Innate Immune Protein (MIIP) technology, which is based on an ultrapure form of bovine lactoferrin (Lactea Lf). Pentagum acts as a biological barrier to inhibit the formation and persistence of oral biofilms. The development of this technology involves partnerships with Johns Hopkins University and Brigham Young University.
- Brand names
- PentagumL PENTAGUM
Beyond the preview
Go deeper on Pentagum.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pentagum.